[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Janssen Cilag S.A.S.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":63},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100627620","a-study-to-assess-adherence-to-apalutamide-in-metastatic-hormone-sensitive-prostate-cancer-participants-in-france-100627620",false,"NCT07451002","A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France","An OBServational Prospective Study in France: Adherence to APAlutamide in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients in France","OBSAPA","Inclusion criteria:\n\n* Male (based on chromosomal composition at birth) and aged greater than or equal to (\\>=) 18 years.\n* Must have a histologically or cytologically confirmed diagnosis of prostate adenocarcinoma\n* Must have documented metastatic hormone-sensitive prostate cancer (mHSPC)\n* Must have agreed with the treating physician to initiate treatment with apalutamide (plus androgen-deprivation therapy \\[ADT\\]) in accordance with the current product characteristics summary, based on the physician's decision, prior to study inclusion\n* Able to understand the content of the patient information sheet and has provided oral consent for data collection. Has received the information sheet and has not objected to data collection\n* Must have a baseline prostate-specific antigen (PSA) level collected prior to the first administration of apalutamide.\n* Must agree to complete adherence and quality-of-life questionnaires during the study, including before the first administration of apalutamide\n\nExclusion criteria:\n\n* Has already received or is currently receiving apalutamide, or any other androgen receptor pathway inhibitor (ARPI; including but not limited to abiraterone acetate, darolutamide, and enzalutamide) or chemotherapy for mHSPC\n* Has received an investigational drug (including vaccines) or used an invasive investigational medical device within 90 days prior to study start or data collection\n* Is currently receiving active treatment for prostate cancer as part of an interventional study\n* Has received ADT for mHSPC for more than 4 months prior to starting apalutamide treatment\n* Has experienced progression under ADT (and thus became castration-resistant) before starting apalutamide treatment\n* Beneficiary of State Medical Aid \\[AME\\]\n* Does not speak\u002Fread French\n* Under guardianship or curatorship\n* Under judicial protection","MALE","18 Years",{"count":20,"type":21},270,"ESTIMATED","OBSERVATIONAL","This study aims to explore the real-world treatment adherence, persistence of apalutamide, and assess the risk of non-adherence according to the participant's profile and behavior of metastatic hormone-sensitive prostate cancer (mHSPC) participants treated with apalutamide during the first year of continued treatment.",[25,26],"Prostatic Neoplasms","Metastatic Hormone-sensitive Prostate Cancer",[28,29],"Apalutamide","mHSPC","RECRUITING","2026-06-04",{"date":33,"type":34},"2026-06-05","ACTUAL",{"date":36,"type":34},"2025-12-18",{"date":38,"type":21},"2028-01-03",{"name":40,"class":41},"Janssen Cilag S.A.S.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":42},"100539107","benefits-of-individual-physical-activity-intervention-on-health-related-quality-of-life-in-participants-with-chronic-lymphocytic-leukemia-100539107","NCT06299540","Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia","Benefits of an Individual Physical Activity Intervention on Health-related Quality of Life in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib in Real-life Practice","QOLIBRI","Inclusion Criteria:\n\n* Participants newly treated with ibrutinib for first line or relapsed CLL (treatment is being initiated or has been initiated within the last 8 days as a maximum)\n* Participants agreed to follow the individual physical activity intervention (IPAI)\n* Participants using or having access to a compatible and appropriate electronic device such as smartphone, laptop or tablet\n* Participants with Internet access at home and email address\n* Participants agreed to wear a connected watch 24 hours a day for all the duration of the study\n\nExclusion Criteria:\n\n* Pregnant participants or planning to become pregnant while enrolled in this study\n* Participants with inability or deemed unsafe to practice physical activity\n* Participants who have received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 90 days before the inclusion visit\n* Participants who are currently involved in an interventional study\n* Participants with probable difficulties in using the digital tool autonomously","ALL",{"count":53,"type":21},180,"The purpose of this study is to assess the impact of an individual physical activity intervention (IPAI) on health-related quality of life (HRQoL) in participants with first line or relapsed chronic lymphocytic leukemia (CLL) initiating ibrutinib in a routine clinical practice setting. HRQoL will be measured using functional assessment of cancer therapy - general scale (FACT-G).",[56],"Leukemia, Lymphocytic, Chronic, B-Cell",{"date":33,"type":34},{"date":59,"type":34},"2024-05-27",{"date":61,"type":21},"2027-10-29",{"name":40,"class":41},""]